Suppr超能文献

血清 P-选择素对冠心病合并高血压患者 PCI 后血压控制的影响。

Impacts of serum P-selectin on blood pressure control after PCI in patients with coronary heart disease complicated with hypertension.

机构信息

Department of General Medical, Shaoxing People's Hospital (Shaoxing Hospital of Zhejiang University), Shaoxing, China.

出版信息

Eur Rev Med Pharmacol Sci. 2017 Jul;21(3 Suppl):78-83.

Abstract

OBJECTIVE

We analyzed the impact of potent anti-hypertension or anti-thrombotic therapy after PCI in patients with coronary heart disease complicated with hypertension, whilst to reflect the prognosis by testing P-selectin.

PATIENTS AND METHODS

A total of 177 patients with coronary heart disease (CHD) complicated with hypertension was continuously enrolled in this study and randomly divided into traditional anti-hypertension group (group A: 130/80 mm Hg ≤ BP ≤ 140/90 mm Hg; anti-hypertensive drugs: β blockers and angiotensin converting enzyme inhibitor, n=84) and potent anti-hypertension group (group B: BP <130/80 mm Hg; dosage and frequency in group B > group A, n=93). This study was approved by the Ethics Committee of Shaoxing People's Hospital. Signed written informed consents were obtained from all participants before the study. Patients who need a stent placed (CAG shows narrowed vascular diameter ≥75%) have to continuously be followed-up for one year. Standard anti-hypertension (fluctuation of BP <5 mm Hg measured for 3 successive days) was detected respectively at admission and inpatient. The blood pressure, low-density lipoprotein cholesterin (LDL-C), high-sensitivity C-reactive protein (hs-CRP) and P-selectin levels were tested 1 month and 1 year after discharge; the time of adverse events (AEs) was also recorded.

RESULTS

There were no statistical differences between the occurrence times of AEs between group A and B (p=0.946). The P-selectin [(83±21) vs. (69±16) μg/L, p=0.038], systolic pressure [(134±8) vs. (119±13) mm Hg, p<0.001] and diastolic pressure [(85±6) vs. (70±5) mm Hg] in group A were higher (p=0.001) than those of group B. Compared with P-selectin ≥50.00 μg/L, the median survival time (>12 vs. 10 months, χ2=3.621, p=0.047) of P-selectin <50.00 μg/L was longer. By comparing P-selectin in different SBP grading (<120 mm Hg, 120-130 mm Hg, 130-140 mm Hg), the difference was statistically significant (χ2=12.912, p=0.002).

CONCLUSIONS

Potent anti-hypertension may influence the occurrence time of AEs after PCI in patients with coronary heart disease complicated hypertension. P-selectin can be a sensitive indicator. SBP has an apparent "J-curve effect" and an appropriate anti-hypertensive scope (120-130 mm Hg).

摘要

目的

我们分析了经皮冠状动脉介入治疗(PCI)后强效降压或抗栓治疗对合并高血压的冠心病患者的影响,并通过检测 P-选择素来反映预后。

患者和方法

连续纳入了 177 例合并高血压的冠心病患者(CHD),并将其随机分为传统降压组(A 组:血压 130/80mmHg≤BP≤140/90mmHg;降压药物:β受体阻滞剂和血管紧张素转换酶抑制剂,n=84)和强效降压组(B 组:BP<130/80mmHg;B 组的剂量和频率大于 A 组,n=93)。本研究经绍兴市人民医院伦理委员会批准。所有参与者在研究前均签署了书面知情同意书。需要置入支架的患者(CAG 显示血管直径狭窄≥75%)需要持续随访 1 年。分别在入院和住院期间检测标准降压(连续 3 天血压测量波动<5mmHg)。出院后 1 个月和 1 年检测血压、低密度脂蛋白胆固醇(LDL-C)、高敏 C 反应蛋白(hs-CRP)和 P-选择素水平;记录不良事件(AE)发生时间。

结果

A 组和 B 组的 AE 发生次数无统计学差异(p=0.946)。A 组的 P-选择素[(83±21)vs.(69±16)μg/L,p=0.038]、收缩压[(134±8)vs.(119±13)mmHg,p<0.001]和舒张压[(85±6)vs.(70±5)mmHg]均高于 B 组(p=0.001)。与 P-选择素≥50.00μg/L 相比,P-选择素<50.00μg/L 的中位生存时间(>12 个月 vs. 10 个月,χ2=3.621,p=0.047)更长。比较不同收缩压分级(<120mmHg、120-130mmHg、130-140mmHg)的 P-选择素,差异有统计学意义(χ2=12.912,p=0.002)。

结论

强效降压可能会影响合并高血压的冠心病患者 PCI 后 AE 的发生时间。P-选择素可能是一个敏感指标。收缩压有明显的“J 型曲线效应”,适当的降压范围(120-130mmHg)。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验